Drug Trial Radar · NCT07940777
A Study to Evaluate the Safety and Efficacy of Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Dec 29, 2026
Primary completion
Jul 21, 2029
Study completion Jul 19, 2032
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate the safety and efficacy of Mavacamten in adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM)
Conditions
- Non-obstructive Hypertrophic Cardiomyopathy
Interventions
MavacamtenDrug
Specified dose on specified days
PlaceboOther
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Peak Oxygen Consumption (pVO2)Time frame: At Week 48
- Change from baseline in Kansas City Cardiomyopathy Questionnaire, 23-item (KCCQ-23 CSS)Time frame: At Week 48
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.